Current Smoking and Reduced Mortality in Bacteremic Pneumococcal Pneumonia: A Population-Based Cohort Study

Chest

Volumn 150, Issue 3, 2016, Pages 652-660

  Beatty, Jessica A ^a   Majumdar, Sumit R ^a   Tyrrell, Gregory J ^a,b   Marrie, Thomas J ^c   Eurich, Dean T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b PROVINCIAL LABORATORY FOR PUBLIC HEALTH   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

mortality; pneumococcus; pneumonia; serotypes; smoking

Indexed keywords

ADULT; ARTICLE; CANADA; CASE FATALITY RATE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HOSPITAL MORTALITY; HUMAN; IN-HOSPITAL MORTALITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; SMOKING; STREPTOCOCCUS PNEUMONIA; AGED; ALBERTA; BACTEREMIA; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; ODDS RATIO; SEROTYPE; STATISTICAL MODEL; STREPTOCOCCUS PNEUMONIAE;

ADULT; AGED; ALBERTA; BACTEREMIA; COHORT STUDIES; FEMALE; HOSPITAL MORTALITY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PNEUMONIA, PNEUMOCOCCAL; PROSPECTIVE STUDIES; REGISTRIES; SEROGROUP; SMOKING; STREPTOCOCCUS PNEUMONIAE;

EID: 84995611282     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.04.020     Document Type: Article

References (38)

1. 1 Lynch, J.P. 3rd, Zhanel, G.G., Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 30:2 (2009), 189–209.
2. 2 Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network Streptococcus pneumoniae, 2014. http://www.cdc.gov/abcs/reports-findings/survreports/spneu14.pdf. Accessed November 1, 2015.
3. 3 Hamborsky, J., Kroger, A., Wolfe, S., Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed., 2015, Public Health Foundation, Washington DC.
4. 4 Fica, A., Bunster, N., Aliaga, F., et al. Bacteremic pneumococcal pneumonia: serotype distribution, antimicrobial susceptibility, severity scores, risk factors, and mortality in a single center in Chile. Braz J Infect Dis 18:2 (2014), 115–123.
5. 5 Marrie, T.J., Wu, L., Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest 127:4 (2005), 1260–1270.
6. 6 Fisman, D.N., Abrutyn, E., Spaude, K.A., Kim, A., Kirchner, C., Daley, J., Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 42:8 (2006), 1093–1101.
7. 7 Garau, J., Baquero, F., Perez-Trallero, E., et al. Factors impacting on length of stay and mortality of community-acquired pneumonia. Clin Microbiol Infect 14:4 (2008), 322–329.
8. 8 Bello, S., Menendez, R., Torres, A., et al. Tobacco smoking increases the risk for death from pneumococcal pneumonia. Chest 146:4 (2014), 1029–1037.
9. 9 Inoue, Y., Koizumi, A., Wada, Y., et al. Risk and protective factors related to mortality from pneumonia among middleaged and elderly community residents: the JACC Study. J Epidemiol 17:6 (2007), 194–202.
10. 10 Lange, P., Vestbo, J., Nyboe, J., Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. Eur Respir J 8:10 (1995), 1694–1698.
11. 11 Katanoda, K., Marugame, T., Saika, K., et al. Population attributable fraction of mortality associated with tobacco smoking in Japan: a pooled analysis of three large-scale cohort studies. J Epidemiol 18:6 (2008), 251–264.
12. 12 Huttunen, R., Heikkinen, T., Syrjanen, J., Smoking and the outcome of infection. J Intern Med 269:3 (2011), 258–269.
13. 13 Grau, I., Ardanuy, C., Calatayud, L., Schulze, M.H., Linares, J., Pallares, R., Smoking and alcohol abuse are the most preventable risk factors for invasive pneumonia and other pneumococcal infections. Int J Infect Dis 25 (2014), 59–64.
14. 14 Tyrrell, G.J., Lovgren, M., Chui, N., et al. Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006. Vaccine 27:27 (2009), 3553–3560.
15. 15 Werno, A.M., Murdoch, D.R., Medical microbiology: laboratory diagnosis of invasive pneumococcal disease. Clin Infect Dis 46:6 (2008), 926–932.
16. 16 Surveillance & Assessment Branch Alberta health. interactive health data application: population estimates. http://www.ahw.gov.ab.ca/IHDA_Retrieval/ihdaData.do. Accessed September 4, 2015.
17. 17 Johnstone, J., Tyrrell, G.J., Marrie, T.J., Garg, S., Kellner, J.D., Streptococcus pneumoniae Alberta Team (SPAT) group. Streptococcus pneumoniae meningitis in Alberta pre- and postintroduction of the 7-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol 22:4 (2011), 137–141.
18. 18 Majumdar, S.R., McAlister, F.A., Eurich, D.T., Padwal, R.S., Marrie, T.J., Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ, 333(7576), 2006, 999.
19. 19 Eurich, D.T., Sadowski, C.A., Simpson, S.H., Marrie, T.J., Majumdar, S.R., Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. ThAm J Med 123:1 (2010), 47–53.
20. 20 Lund, E., Henrichsen, J., Laboratory diagnosis, serology and epidemiology of Streptococcus pneumoniae. Bergan, T., Norris, J.R., (eds.) Methods in Microbiology, Vol. XII, 1978, Academic Press, New York.
21. 21 Mandell, L.A., Wunderink, R.G., Anzueto, A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44:suppl 2 (2007), S27–S72.
22. 22 Asadi, L., Eurich, D.T., Gamble, J.M., Minhas-Sandhu, J.K., Marrie, T.J., Majumdar, S.R., Guideline adherence and macrolides reduced mortality in outpatients with pneumonia. Respir Med 106:3 (2012), 451–458.
23. 23 Flory, J.H., Joffe, M., Fishman, N.O., Edelstein, P.H., Metlay, J.P., Socioeconomic risk factors for bacteraemic pneumococcal pneumonia in adults. Epidemiol Infect 137:5 (2009), 717–726.
24. 24 Weinberger, D.M., Harboe, Z.B., Sanders, E.A., et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 51:6 (2010), 692–699.
25. 25 Naucler, P., Darenberg, J., Morfeldt, E., Ortqvist, A., Henriques Normark, B., Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax 68:6 (2013), 571–579.
26. 26 Ruiz, L.A., Zalacain, R., Capelastegui, A., et al. Bacteremic pneumococcal pneumonia in elderly and very elderly patients: host- and pathogen-related factors, process of care, and outcome. J Gerontol A Biol Med Sci 69:8 (2014), 1018–1024.
27. 27 Vanderkooi, O.G., Church, D.L., MacDonald, J., Zucol, F., Kellner, J.D., Community-based outbreaks in vulnerable populations of invasive infections caused by Streptococcus pneumoniae serotypes 5 and 8 in Calgary, Canada. PLoS One, 6(12), 2011, e28547.
28. 28 Shigayeva, A., Rudnick, W., Green, K., et al. Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs. Clin Infect Dis 63 (2016), 139–147.
29. 29 Tomczyk, S., Bennett, N.M., Stoecker, C., et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Weekly Rep 63:37 (2014), 822–825.
30. 30 Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:5 (1987), 373–383.
31. 31 Bogaert, D., De Groot, R., Hermans, P.W., Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4:3 (2004), 144–154.
32. 32 Nuorti, J.P., Butler, J.C., Farley, M.M., et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 342:10 (2000), 681–689.
33. 33 Stampfli, M.R., Anderson, G.P., How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol 9:5 (2009), 377–384.
34. 34 Meichtry, J., Born, R., Kuffer, M., et al. Serotype epidemiology of invasive pneumococcal disease in Swiss adults: a nationwide population-based study. Vaccine 32:40 (2014), 5185–5191.
35. 35 Regev-Yochay, G., Paran, Y., Bishara, J., et al. Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: a nationwide surveillance study. Vaccine 33:9 (2015), 1135–1142.
36. 36 Cole, S.R., Platt, R.W., Schisterman, E.F., et al. Illustrating bias due to conditioning on a collider. Int J Epidemiol 39:2 (2010), 417–420.
37. 37 VanderWeele, T.J., Robins, J.M., Directed acyclic graphs, sufficient causes, and the properties of conditioning on a common effect. Am J Epidemiol 166:9 (2007), 1096–1104.
38. 38 Whitcomb, B.W., Schisterman, E.F., Perkins, N.J., Platt, R.W., Quantification of collider-stratification bias and the birthweight paradox. Paediatr Perinat Epidemiol 23:5 (2009), 394–402.